RNA Therapeutics

Sponsored by: BIA Separations & eTheRNA Immunotherapies

Bolstering the latest advances and opportunities in RNA-based medicine

The RNA therapeutics industry has grown at an exponential rate in recent years, with an increased spotlight following the industry’s leading role in developing vaccines against COVID-19 in response to the global pandemic. This year’s conference will reflect on how the industry has adapted and played a pivotal role in global health over the past year and will discuss the takeaways for future mRNA therapeutic development.

The 2022 agenda will explore innovations in novel and targeted delivery, RNAi innovations and antisense oligonucleotide therapeutics. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of RNA with case studies on the treatment of cardiovascular disease, neurological diseases, and oncology.

Join us in February 2022, as SMi’s 13th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments of the industry.

Benefits of Attending:
•Explore how mRNA vaccines have led the way in the response against COVID-19 and key takeaways for the industry
•Understand the potential of RNAi and antisense oligonucleotides for the treatment of cardiovascular and neurological diseases
•Delve into the latest innovations in novel RNA delivery and target specificity
•Engage in the growing advances and development of RNA tools for vaccines and anti-infectives.

View the full agenda and speaker line-up online: www.therapeutics-rna.com/evvnt
Hashtag: #SMiRNA
Chair for 2022:
Heinrich Haas, VP RNA Formulation and Drug Delivery, BioNTech

Featured speakers:
•Jimmy Weterings, Principal Scientist Oligonucleotide Chemistry, AstraZeneca
•Thomas Thum, Founder and Chief Scientifi c Officer, Cardior Pharmaceuticals
•Samir Ounzain, CEO, Haya Therapeutics
•David Lowe, Vice President, Research, Evox Therapeutics
•Alfi ca Sehgal, Vice President, Head of Discovery, CAMP4 Therapeutics
•Punit Seth, Vice President, Medicinal Chemistry, Ionis Pharmaceuticals
•Nagy Habib, Head of HBP Surgery, Co-Founder, Imperial College London and MiNA Therapeutics
•Dong Ki Lee, CEO, OliX Therapeutics
•Martin Akerman, Chief Technology Offi cer & Co-Founder, Envisagenics

Who should attend:
•Research & Development Directors/Managers/Scientists
•Heads of Clinical Development
•Heads of Pre-Clinical Development
•Head of RNA Biology
•Head of RNA Formulation and Drug Delivery
•Head of Pre-clinical R&D
•Head of New Modalities
•Head of Discovery
•Senior Scientists
•Chief Scientific Officers
•Chief Medical Officers

Registrations can be made on the event website at: www.therapeutics-rna.com/evvnt

Others Details

URLs:
Brochure: https://go.evvnt.com/906162-3?pid=6581
Booking: https://go.evvnt.com/906162-4?pid=6581
Sponsor: https://go.evvnt.com/906162-5?pid=6581